Parker, E.T. Lollar, P. Conformation of the von Willebrand factor/factor VIII complex in quasi-static flow. J. Biol. Chem. In press
Zakas, P.M., Healey, J.F., Smith, I.W., Lillicrap, D., Lollar, P. Sedimentation velocity analytical ultracentrifugation of oxidized recombinant full-length factor VIII. 2020 Front Immunol. 11:150-156.
Smith, I.W., d'Aquino, A.E., Coyle, C.W., Fedanov, A., Parker, E.T., Denning, G., Spencer, H.T., , Lollar, P., Doering, C.B., Spiegel, P.C., Jr. The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. 2019 J Thromb Haemost. 18:57-69.
Schureck, M. A., Meisner, J., Hoffer, E. D., Wang, D. X., Onuoha, N., Cho, S. E., Lollar, P., Dunham, C. M. Structural basis of transcriptional regulation by the HigA antitoxin. 2019 Molecular Microbiology 111: 1449-1462.
Doering, C.B., Denning, G., Shields, J.E., Fine, E.J., Parker, E.T., Srivastava, A., Lollar, P., Spencer, H.T. Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A. 2018 Hum Gene Therapy 29, 1183-1201
Batsuli, G., Ito, J., Mercer, R., Baldwin, W.H., Cox, C., Parker, E.T., Healey, J.F., Lollar, P., Meeks, S.L. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model. 2018 J. Thromb. Haemost. 16, 1779-1788.
Healey, J.F., Parker, E.T., Lollar P. Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation. 2018. J. Thromb. Haemost. 16, 303-315.